Up more than 42% year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI), one of the largest biotechnology ETFs, is one of this year’s best-performing non-leveraged ETFs. That does not mean XBI’s run is over. Some market observers argue the opposite is true. Biotech ETFs soared even...